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A B S T R A C T   
Adults with central adiposity and other features of the metabolic syndrome have a markedly elevated risk of 
developing type 2 diabetes (T2D) and cardiovascular disease (CVD). A Mediterranean-style healthy eating 
pattern (MED-HEP) and consumption of foods with a lower glycemic index (GI) are potential dietary approaches 
to curb the T2D and CVD epidemic. However, experimental evidence of the effectiveness of MED-HEP and of the 
contribution of GI towards improving indices of glucose homeostasis, especially among non-diabetic people, are 
lacking. Therefore, we developed the MedGI-Carb trial, a multi-center (Italy, Sweden, and United States) 
intervention in adults with at least two components of the metabolic syndrome (elevated waist circumference +
one other component) that aims to improve markers of glucose homeostasis through dietary modification. All 
participants were randomized to consume an isocaloric high- or low-GI MED-HEP for 12 weeks. We hypothesized 
that indexes of insulinemia (primary outcome: postprandial insulin and glucose after standardized breakfast and 
lunch; secondary outcomes: fasting plasma glucose and insulin, HbA1c, 24-h continuous glucose monitoring) 
would be improved more with the low-GI versus the high-GI MED-HEP. Additionally, we hypothesized that 
consumption of a MED-HEP would improve other markers of cardiometabolic health and well-being (fasting 
blood pressure, fasting lipid profile, sleep quality, satiety, global metabolic alterations in the plasma metab-
olome, changes in the gut microbiota, subjective health and well-being), with no difference between groups. 
Collectively, the design of MEDGI-Carb allows several different research questions to be explored. TRIAL 
REGISTRATION: ClinicalTrials.gov identifier: NCT03410719.   
1. Introduction 
The global burden of type 2 diabetes mellitus (T2D) ballooned from 
30 million in 1985 to 463 million in 2019 [1,2]. This is particularly 
troubling given the close association between T2D and cardiovascular 
disease (CVD) — the leading cause of morbidity and mortality in the 
United States and in many other Western countries [3]. The traditional 
medical establishment is struggling to handle this burden, necessitating 
redoubling research efforts to develop effective and sustainable lifestyle 
interventions — of which consuming healthier diets feature prominently 
— to curb this epidemic [4–8]. Postprandial glycemic and insulinemic 
responses are firmly implicated in the development of T2D and CVD [9, 
10]. Among factors influencing postprandial glycaemia, the glycemic 
index (GI) of the carbohydrate source is posited to play a central role 
[11]. However, the utility and relevance of the GI, particularly in the 
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context of a mixed diet for people without T2D, has been a subject of 
debate for decades [12–15]. Specifically, GI has been questioned on 
counts of: failure to consider the insulin response [16], the high intra- 
and inter-subject variation in glucose response to a food [17], and a loss 
of discriminating power when foods are combined in a mixed meal [18]. 
Given the shift towards increased focus on eating patterns rather than 
specific foods or nutrients, it is of relevance to determine the impact of 
different GI foods in the context of a healthy eating pattern (HEP), 
especially considering the benefits of a low GI diet may be less pro-
nounced in the presence of other health-promoting dietary features 
[19]. 
One such healthy eating pattern is a Mediterranean-style (MED) HEP 
— a pattern broadly emphasizing intake of fruits, vegetables, olive oil, 
and moderate intake of animal products — which has recently been 
touted as a fount of cardiometabolic wellness and is recommended by 
the World Health Organization [20] and other governmental bodies 
[21]. There is ample evidence that the MED HEP effectively promotes 
cardiometabolic health and wellness [22,23], and reduces risk of 
developing T2D [24,25]. However, there is currently limited experi-
mental evidence supporting a MED HEP, underscored by a notable 
paucity of evidence supporting this eating pattern in populations other 
than from the MED region. To our knowledge, there have been no 
studies where low GI foods have been combined with a MED HEP. 
Therefore, we developed a multi-center intervention study in adults 
with components of metabolic syndrome, i.e. at risk for development of 
diabetes, that aims to improve glycemic responses through modification 
of carbohydrate quality in the context of an overall healthy MED HEP. 
The purpose of the present study was to investigate differential effects of 
a low- vs high-GI MED HEPs on cardiometabolic health and well-being 
among participants with at least two features of the metabolic syn-
drome, as they are at greater risk of developing T2D and CVD [26]. 
During the intervention, all participants consumed an energy-sufficient 
MED HEP (based on criteria to be designated as a USDA Healthy Med-
iterranean Eating Pattern), differing only in the GI of half of the 
carbohydrate-foods provided in the diet. We hypothesized that the 
reduction in postprandial insulin and glucose responses would be 
greater for the low-GI versus high-GI MED HEP after the 12-week 
intervention. Additionally, we hypothesized that consumption of a 
MED HEP would result in comparable improvements in indices of car-
diometabolic risk factors including fasting blood pressures, fasting 
serum lipid profile, glucose, insulin, hemoglobin A1c (HbA1c), and 24-h 
continuous interstitial glucose monitoring. Further, we plan to assess the 
potential for low-GI HEPs to differentially improve global metabolic 
alterations as detected in the plasma metabolome and composition of 
gut microbiota. 
2. Methods/design 
The MEDGI-Carb trial is an international multi-center randomized, 
controlled, parallel group, 15-week trial including a 3-week baseline 
testing period followed by 12 weeks of controlled dietary intervention 
(Fig. 1). This research study was initiated in January 2018 and the trial 
continued through December 2019. This study consisted of three centers 
at 1) Federico II University - Naples, Italy 2) Chalmers University of 
Technology - Gothenburg, Sweden, and 3) Purdue University - West 
Lafayette, IN, USA. This design allowed us to investigate the effects of GI 
in the context of a HEP in different settings and food environments. The 
study protocol was approved by the institutional review board of Fed-
erico II University, the Regional Ethical Review Board, Gothenburg, 
Sweden, and the biomedical institutional review board at Purdue Uni-
versity. This study is registered in the public trial registry Clinicaltrials. 
gov as NCT03410719. 
2.1. Experimental design 
During the intervention period, subjects consumed a controlled, iso- 
caloric weight-maintenance diet and were instructed to consume 
intervention-specific foods to achieve a low-glycemic or high-glycemic 
MED HEP (low-GI or high-GI, respectively). During baseline and post- 
intervention assessments, the diet, general health, sleep quality, fecal 
microbiota profile, and blood pressure were assessed. Outcome mea-
surements were obtained on testing days to determine markers of 
glucose homeostasis by completion of an 8-h meal glucose tolerance test 
(MGTT) including both breakfast and lunch resembling food choices of 
the assigned diet, an oral glucose tolerance test (OGTT), and continuous 
glucose monitoring (CGM) at baseline, mid-point (only in USA), and 
post-testing. Follow-up data of eating pattern, sleep quality, and general 
health and well-being were collected either personally or via email or 
regular postal services 3 months after completion of the 12-week 
controlled intervention period. All subjects were instructed to main-
tain their habitual types and levels of physical activities. 
2.2. Eligibility criteria 
The eligibility criteria were designed to select middle-aged and older 
adults at risk for developing CVD or T2D. Therefore, adults with waist 
circumference >102 cm (males) or > 88 cm (females) and one addi-
tional feature of the Metabolic Syndrome according to ATP [III] [27]: 
including blood pressure >130/85 mmHg or taking medication to 
control high blood pressure, fasting plasma glucose 100–126 mg/dL, 
fasting triglycerides 150–400 mg/dL, HDL cholesterol <40 mg/dL 
(males) or <50 mg/dL (females), were recruited. Additional study in-
clusion criteria were as follows: age 30–69 y, BMI 25–37 (kg/m2), 
weight stable (±3 kg in previous 3 months), no acute illness, no car-
diovascular events (myocardial infarction or stroke) during the 6 
months prior to the study, not anemic (hemoglobin >12 g/dL), no renal 
or liver failure (creatinine <1.7 mg/dl and alanine amino-
transferase/aspartate aminotransferase <2 times than normal values, 
respectively), not diabetic, not pregnant or lactating, not a vegetarian or 
consuming a diet incompatible with protocol diets, not smoking >20 
cigarettes per day, not involved in a stable intensive physical activity 
regimen (<3 h/week of moderate or high intensity resistance or aerobic 
exercise training), Subjects taking antihypertensive and statin drugs 
were asked to keep the type and dosage of medication unchanged 
throughout the study period, or to notify research investigators soon 
after physician-directed changes were made. 
Abbreviation list 
Abbreviation Meaning 
CGM Continuous glucose monitoring 
CV Coefficient of variation 
CVD Cardiovascular disease 
ESS Epworth Sleepiness Scale 
GI Glycemic index 
HEP Healthy eating pattern 
IPAQ International Physical Activity Questionnaire 
MED Mediterranean 
MGTT Meal glucose tolerance test 
NDSR Nutrient Data System for Research 
OGTT Oral glucose tolerance test 
PSQI Pittsburgh Sleep Quality Index 
TP Time point 
T2D Type 2 diabetes 
SF-36v2 Medical Outcomes Study 36-item short-form 
questionnaire  
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2.3. Recruitment 
Due to the different environments of the three centers, the recruit-
ment and onboarding process varied by site. 
The Italian center: To reach potential participants, information on 
the study was sent to all University employees through the administra-
tion’s profiling database, and by displaying some specific leaflets around 
the “Federico II” University Hospital. In addition, participants of pre-
vious experimental studies were also invited to participate, as well as 
patients from hypertension, dyslipidemia and obesity clinics of the 
University Hospital. Participants who responded to advertisement were 
invited to the testing facilities of the Diabetes, Nutrition and Metabolism 
Unit for a screening visit in order to verify inclusion and exclusion 
criteria. The potential participants were invited to participate in the 
study. 
The Swedish center: Participants from the Swedish site were 
recruited via internet postings and advertising in the Gothenburg area. 
Participants were sought via the press, announcements and leaflets. 
Further detailed information about the study were sent by email or 
regular mail to all people who responded to advertisements. If possible, 
people interested in participation were contacted by e-mail or telephone 
for a pre-screening according to the inclusion/exclusion criteria and any 
interested volunteer who expressed willingness to participate in the 
study was scheduled for a screening visit at the clinical laboratory of the 
Department of Clinical Nutrition, Sahlgrenska Academy, University of 
Gothenburg, where the study was conducted. Anthropometric and blood 
pressure measurements were taken. A blood sample was drawn for 
analysis of health parameters needed for the evaluation of inclusion/ 
exclusion. Potential participants completed also a medical history 
questionnaire and demographic form. 
The United States center: Numerous mediums were used to reach 
potential participants. Physical advertisements such as flyers were 
posted around the greater Lafayette, IN area. Online advertisements on 
Purdue University websites were posted. A professional study recruit-
ment service specializing in social media marketing was contracted 
(Trialfacts©, Australia). A multi-step process was used to recruit po-
tential participants in this research study. Participants who responded to 
advertisement were sent a pre-screening form and the opportunity to 
provide consent for us to send them a medical history questionnaire to 
obtain more in-depth information. After reviewing both the prescreen-
ing form and the completed medical history questionnaire, participants 
who qualified were invited to the testing facilities on the Purdue Uni-
versity campus in West Lafayette, IN for a screening visit. Should par-
ticipants qualify based on the additional information gained from the 
anthropometric and blood results collected from the screening visit, all 
information was sent to a study physician. Should the study physician 
deem it safe for a potential participant to proceed, the potential 
participant would be invited to enroll in the study. 
2.4. Informed consent procedure 
All procedures for obtaining consent were reviewed and approved by 
the Federico II University Institutional Review Board, Naples, Italy (IRB 
Protocol #175/17), the Regional Ethical Review Board, Gothenburg, 
Sweden (IRB Protocol #663–17), and the Purdue University Biomedical 
Institutional Review Board (IRB Protocol #1610018310). 
All potential participants were screened for eligibility and given 
opportunities to voice any questions or concerns. If a potential partici-
pant qualified based on the results from the screening visit and physician 
review, they were invited to join the study. If the participant accepted 
the invitation, a study orientation day was scheduled where participants 
first reviewed the study-consent documentation with a researcher and 
were given opportunities to voice any questions or concerns. Pending 
any concerns, participants then signed a consent form with a data clause 
allowing researchers to analyze samples for variables not specified in the 
primary aims (e.g. this consent form would permit determination of 
triglycerides). 
2.5. Randomization 
A member of the research team at each of the three testing sites who 
was not involved in data collection or analysis generated the random 
allocation sequence and assigned subjects to the interventions. Each 
subject was randomly assigned to one of two dietary groups using either 
a stratified block pattern (Italy & US; n = 8, 10 blocks; 4 randomized to 
each group per block of 8, using an online randomization plan generator; 
http://randomization.com/) or mixed size of the block pattern (Sweden; 
4, 6, and 8 subjects per block in random block order; using Rstudio 
Fig. 1. Study Schematic of the MedGI-Carb-trial, a randomized single-blinded controlled trial assessing the effects of low-versus high-glycemic index in the context of 
a Mediterranean-style healthy eating pattern. CGM, continuous glucose monitoring; MGTT, meal glucose tolerance test; OGTT, oral glucose tolerance test. Blood 
panel includes complete metabolic panel (fasting glucose, GFR, etc.) and lipids & lipoprotein profile; questionnaires include the International Physical Activity 
Questionnaire, Health and Well-being (SF-36v2) Questionnaire, Pittsburgh Sleep Quality Questionnaire, Epworth Sleepiness Scale, and the Mediterranean Diet 
Assessment Tool. 
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software version 2.4.0 with package ‘blockrand’ version 1.3). The 
randomization code remained unrevealed until all participant testing 
and analyses of samples for a priori cardiometabolic outcomes were 
completed. 
2.6. Dietary assessment 
All participants completed a 14-item MED Diet Assessment Tool, 
adapted from the PREDIMED trial [28], to determine adherence to the 
MED HEP while consuming self-selected diets. Center-specific proced-
ures for dietary assessments are provided below. 
The Italian center: Dietary intakes were assessed by a four-day di-
etary record (three working days and one weekend day) at baseline and 
at weeks 4, 8, and 12 during the intervention, and 3 months after the 
intervention. Dietary-record data were entered into the Metadieta 4.0 
software (METEDA S.r.l., San Benedetto del Tronto, Italy) for determi-
nation of food and nutrient intake assessed based on the Italian food 
composition table. 
The Swedish center: The subjects reported their food intake by four- 
day food records (three working days and one weekend day) with 
portion estimation at baseline and after 4-week of intervention, at post- 
testing week and 3 months after the intervention. To determine the 
nutritional composition of the reported food intake, the Dietist Net Pro 
software (Kost och Näringsdata AB, Bromma, Sweden) with nutrient 
information from the Swedish Food Composition Database, was used. 
The United States center: Dietary intakes were assessed via three-day 
dietary recalls on non-consecutive days during baseline weeks and 3 
months after completing the intervention. A registered dietitian at the 
Purdue Bionutrition center contacted participants at unannounced times 
to attenuate the observer effect (aka Hawthorne effect). Dietary recall 
data were entered into the Nutrient Data System for Research (NDSR; 
University of Minnesota, NCC. Minneapolis, MN) for determination of 
food and nutrient intakes. Healthy Eating Index of participant dietary 
recalls and sample menus were calculated by inputting NDSR outputs 
into SAS program code provided by the United States National Institutes 
of Health, National Cancer Institute (https://epi.grants.cancer.gov/h 
ei/sas-code.html). 
2.7. Dietary compliance 
During the 3-week baseline period, all subjects consumed their 
habitual, self-chosen, unrestricted diets. Throughout the 12-week 
intervention period, each subject was counseled to follow their 
assigned iso-caloric MED HEP using a combination of prescribed menus 
(breakfast, lunch, and snack eating occasions) and an item specific 
version of the ‘Dinner Recipe Builder’ for dinner. The ‘Dinner Recipe 
Builder’ bestowed greater freedom to participants with the goal of 
reducing burnout, allowing them to mix and match ingredients while 
still following a MED HEP. A sample ‘Dinner Recipe Builder’ (low-GI 
group) is provided in Supplemental Table 1. The two group-specific diet 
plans contained primarily the same foods and beverages typically 
included in MED HEPs (adjusted to local eating habits and food pref-
erences), except for substitutions of major sources of starch in the meals: 
high-GI – jasmine rice, potato, mashed potatoes, cous-cous, wholegrain 
bread and rusks; low-GI – pasta, brown rice, flat bread, and wheat plus 
rye bread and seeds. All diet-related activities and assessments were 
performed in conjunction with the Indiana Clinical Research Center 
Bionutrition Facility at Purdue University, the Diabetes, Nutrition and 
Metabolism Unit at Federico II University of Naples and at the Clinical 
Nutrition facilities at Sahlgrenska Academy, University of Gothenburg. 
The overarching goals were to have all participants in both groups 
consume a MED HEP with the same quantities of metabolizable carbo-
hydrate (270 g/d) and fiber, and sufficient total energy for weight 
maintenance. Higher or lower energy content was achieved through 
modulation of dietary fat and protein. One-half of daily carbohydrate 
(135 g) was the same between low-GI and high-GI groups, including 
carbohydrates in fruits, vegetables, and other foods that all subjects 
consumed. The other one-half of daily carbohydrate intake (135 g) was 
specific to the low-GI and high-GI groups. Specifically, 135 g of carbo-
hydrate in the low-GI group came from foods with GI values < 55, while 
135 g of CHO in the high-GI group came from foods with GI values > 70. 
The intervention specific carbohydrates were distributed as 35 g at 
breakfast, 40 g at lunch, and 60 g at dinner. Dietary fiber was held at 35 
g/d (range of 32–38 g/d) for both intervention groups. The specific 
means of achieving dietary control varied slightly among centers, 
dependent upon their respective research infrastructure and participant- 
lifestyle considerations. Center-specific procedures to achieve dietary 
control are described below. 
The GI values of starchy foods included in the low- and high-GI diets 
were determined following the method described by the Food and 
Agriculture Organization/World Health Organization [29] and, later, 
applying the guidelines set up by the International Standards Organi-
zation [30]. All the analyses were performed at the Department of Food 
Science (Nutrition Unit) of the University of Parma, Italy. A list of the GI 
of starchy foods utilized in the study is provided in Supplemental 
Table 2. 
The Italian center: Dietary counseling included group dinner meal 
preparation sessions every other week. All starchy foods (pasta, wheat 
plus rye bread and seeds, flat bread, brown rice for low GI diet, and 
wholegrain bread, jasmine rice, whole meal rusks, potatoes and mashed 
potatoes for high GI diet) and the extra virgin olive oil to be consumed 
throughout the study period were provided to participants free of 
charge. The individualized menus were developed by a registered die-
titian, using Metadieta software (Meteda s.r.l., Italy). Menus were 
designed to meet criteria to be classified as a MED HEP [31]. Sample 
menus for both the low-GI and high-GI diets are provided in Supple-
mental Table 3. Menu booklets provided to participants to help their 
food choices in agreement to the prescribed diet consisted of 7-d rotating 
menus with food items (in gram amounts) grouped into breakfast, lunch, 
dinner, and snack categories. The target energy intake for each partici-
pant during the study is based on the energy equation for resting energy 
expenditure (MJ/d) according to LARN 2014 [32] multiplied with 
sedentary physical activity (PAL 1.45). Finally presented in total energy 
expenditure kcal/day. Five variants of the standard menu, ranging from 
1700 kcal/d to 3000 kcal/d, were available to address different energy 
needs of the participants. Energy adjustments were performed in case of 
± Δ 3 kg weight change at any point of intervention period. 
The Swedish center: Dietary counseling included group dinner meal 
preparation sessions every other week. All starchy foods (pasta, wheat 
plus rye bread and seeds, flat bread, brown rice, all bran flakes for low GI 
diet, and wholegrain bread, frasrost white bread, jasmine rice, whole- 
meal rusks, cornflakes, mashed potatoes and potatoes for high GI diet) 
and the extra virgin olive oil to be consumed throughout the interven-
tion period were provided to participants free of charge during biweekly 
cooking sessions. Also, snacks such as: almonds, hazel nuts, shredded 
coconut, sunflower seeds, dried apricots, raisins and dried bananas were 
provided free of charge in connection with starchy foods. Subjects were 
limited to 3 servings of alcohol per week. Water and non-energy, 
caffeine-containing beverages were allowed ad libitum during the 
intervention. The individualized menus were developed by a registered 
dietitian, using Dietist Net Pro software (Kost och Näringsdata AB, 
Bromma, Sweden). Sample menus for both the low-GI and high-GI diets 
are provided in Supplemental Table 4. Menu booklets provided to par-
ticipants to help their food choices in agreement to the prescribed diet 
consisted of 7-d rotating menus with food items (in portion estimation) 
grouped into breakfast, lunch, dinner, and snack categories. The target 
energy intake for each participant during the study is based on the en-
ergy equation for resting energy expenditure (MJ/d) according to the 
Nordic Nutrition Recommendations 2012 [33,34] multiplied with 
sedentary physical activity (PAL 1.4). Finally presented in total energy 
expenditure kcal/day. Nine variants of the standard menu, ranging from 
1800 kcal/d to 3600 kcal/d, were available to address different energy 
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needs of the participants. Energy adjustments were performed in case of 
± Δ 3 kg weight change at any point of intervention period. 
The United States center: All study food was provided to participants 
during the 12-week intervention period. Dietary counseling included 
group dinner meal preparation sessions at baseline, conducted at a 
demonstration kitchen and using the ‘Dinner Recipe Builder’ as an in-
struction tool. Subjects were provided with group-specific instructions 
for food preparation. Energy intake prescription was not modified 
(except in extreme cases; ± Δ 3 kg) during the first 4 weeks of the 
intervention period to allow for weight stabilization upon adoption of a 
new diet. The individualized menus were developed by a registered 
dietitian, using NDSR software (University of Minnesota, NCC. Minne-
apolis, MN). Menus were designed to meet criteria to be classified as a 
USDA Healthy Mediterranean Eating Pattern. Sample menus for both the 
low-GI and high-GI diets are provided in Supplemental Table 5. The 
menu booklets provided to participants consisted of 7-d rotating menus 
with food items (in gram amounts) grouped into breakfast, lunch, af-
ternoon snack, dinner, and evening snack categories. Participants were 
instructed to weigh the foods out and check them off in the menu 
booklets when they were consumed. Participants were permitted an 
optional serving of 5 oz. of red wine daily (not prescribed). Herbal 
seasoning of food, water, and non-energy, caffeine-containing beverages 
were allowed ad libitum during the intervention. At the evening meal, 
participants were instructed to circle one item from each row (or two, 
whereby they would split the gram amount) to consume from the 
‘Dinner Recipe Builder’. Each subject’s total energy requirement was 
estimated using the sex-specific equations for normal weight, over-
weight or obese adults with a low activity level (physical activity co-
efficients; male = 1.12; female = 1.16) [35]. The baseline menu was 
established with a daily energy intake of 2400 kcal/d. Five variants of 
the base menu, ranging from 2100 kcal/d to 3300 kcal/d, were offered 
to address different energy needs of participants. 
Intervention-specific foods were provisioned through an online su-
permarket grocery ordering service [36]. Due to the flexibility built into 
the ‘Dinner Recipe Builder’ meal, participants were in frequent contact 
with a research staff member on their grocery requirements. Participants 
were given a grocery order sheet with a pre-filled in column of antici-
pated grocery needs to adhere to the diet, as well as a column for actual 
needs to be filled in by the participant weekly. The research staff 
member would then review and process the grocery order into the online 
service. At a designated time, the research participant would pull into a 
parking space in the supermarket and their entire grocery order would 
be brought to their car. Subjects were provided with all foods, along 
with scales, measurement cups, measurement spoons, and a digital food 
scale. 
2.8. Compliance 
The center-specific procedures to document dietary compliance are 
described below. 
The Italian center: Adherence to diets was evaluated by a four-day 
dietary record at intervention weeks 4, 8, and 12 and was reinforced 
by the dietitians through bi-weekly counseling and weekly phone calls. 
Compliance for participants allocated to high or low GI diets were 
calculated as a percentage of the quantity of starchy foods ingested 
among those prescribed for the high or, respectively, the low GI diet, 
with partial credit assigned to incomplete ingestion of items. 
The Swedish center: Adherence to diets was evaluated by a four-day 
dietary records (after 4-week and at 12-week) and through the use of 
daily menu compliance checklists. Participants were instructed to check- 
off boxes next to the items they consumed during each day of the study 
in the 7-d rotating menu booklets. Participants were instructed to write 
in any deviations from the menus. Compliance was calculated as a 
percentage of all food items ingested, with partial credit assigned to 
incomplete ingestion of items. 
The United States center: During the intervention, dietary 
compliance was assessed formally using daily menu compliance check-
lists and more crudely in real time through review of online grocery 
pickup service orders. The grocery orders were reviewed weekly for 
consistency with the study diet menus. Discrepancies were addressed by 
discussion with participants. Participants were provided with scales and 
measuring cups to weigh out portion sizes for each item on the menu (in 
grams). Participants were instructed to check off boxes next to the items 
they consumed during each day of the study in the 7-d rotating menu 
booklets. If an item was not completely consumed, participants were 
instructed to indicate what percentage of the item was ingested. Par-
ticipants were instructed to write in any additional items consumed not 
part of the provided menus. Menu booklets were reviewed in full at the 
mid-point and post-testing weeks. Compliance was calculated as the 
percentage of all food items ingested, with partial credit assigned to 
incomplete ingestion of items. 
2.9. Cooking classes 
Participants were invited to cooking classes to help them learn to 
cook MED meals and increase self-efficacy in ability to follow an 
intensive dietary intervention. 
The Italian and Swedish centers: Participants were scheduled for 
their first cooking class in the baseline run-in weeks (after MGTT) in 
order to teach them the basic features of the prescribed MED HEP. 
Thereafter, the class was aimed at instructing participants on how pre-
pare a wide variety of recipes utilizing the starchy foods appropriate to 
the assigned diet (i.e. pasta, rice, flat bread, cous-cous) in combination 
with other ingredients (i.e, fat, vegetables, protein sources, herbs) in 
amounts and combinations apt to get the necessary energy and nutrients 
intake. 
The United States center: Participants were scheduled for their first 
cooking class in the baseline run-in weeks. The class was designed to 
help participants prepare the ‘Dinner Recipe Builder’ meal. Participants 
were taught how to prepare a wide variety of recipes utilizing starchy 
foods appropriate to the assigned diet, and how to mix and match in-
gredients on the ‘Dinner Recipe Builder’ to make a suitable meal. The 
first class was mandatory, whereby participants would demonstrate that 
they could effectively prepare meals to adhere to the dietary interven-
tion. Given the wide spread of culinary experience among participants, 
the classes could be considered helpful or basic. Due to this variance, 
attendance to cooking classes beyond the first was encouraged, if helpful 
to participants, but optional. 
2.10. Clinical assessments 
Visits for clinical assessments included a meal glucose tolerance test 
(MGTT), and an oral glucose tolerance test (OGTT) (Fig. 2). Blood 
pressure, anthropometric assessments including waist circumference 
and body composition via air displacement plethysmography (USA) or 
bio-electrical impedance (Italy) were also scheduled to occur while 
participants were at the testing facilities. Prior to all testing days, par-
ticipants were instructed not to eat or drink anything (except a small 
amount of water) from 10:00pm the evening before the visit. Partici-
pants were counseled to refrain from vigorous physical activity for 48 h 
(24 h in Sweden) prior to testing days, avoid alcohol 24 h prior to testing 
days, and avoid caffeinated beverages the morning of testing days. After 
arriving at the testing facilities, participants would be seated in a chair/ 
bed to rest. A catheter was placed in an antecubital vein that remained in 
place for the remainder of the testing day. Blood pressure was taken in 
duplicate after 15 min of rest. If blood pressure measurements differed 
by more than 5 mmHg, a third measurement was taken. The blood 
pressure measurements were then averaged. 
2.10.1. Meal glucose tolerance test 
Participants reported for an 8 h MGTT during baseline, mid-testing 
(USA center only), and post-testing. Double-baseline fasting blood 
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samples were collected at the − 15 min time point (TP) and − 5 TP 
following 15 min of rest. At TP 0, the test meal was consumed in two 
parts, to better control pace of meal consumption. Subjects had 7.5 min 
to consume the first half of the meal, and 7.5 min to consume the second 
half of the meal. Eight ounces of water was included as part of the test 
meals in which subjects were required to consume during the 15 min. 
While the two group-specific dietary plans are adjusted to local eating 
habits and food preferences, the low-GI and high-GI test meals were 
strictly standardized across all three centers. Full test meal food and 
nutrient contents of the test meals are provided in Table 1. 
Blood samples were collected immediately following the test 
breakfast meal (TP+15) and then at intervals progressing from 15 min to 
1 h between blood sampling: TP+30, 45, 60, 90, 120, 180, and 240. The 
second test meal was provided following the TP+240 blood draw, and 
subjects had 15 min to complete the meal (7.5 min per half). The blood 
draw time pattern was then repeated after the second meal was 
consumed. 
Standard visual analog scales were administered hourly, with the 
first administration at the − 5 TP. Subjects responded to prompts to 
assessing subjective feelings of such as their level of hunger, desire to 
eat, and fullness by marking on a 100 mm scale with end descriptors 
ranging from “Not at all” to “Extremely” [37,38]. 
2.10.2. Oral glucose tolerance test 
Participants reported for a 2-h OGTT during baseline, mid-testing 
(USA center only), and post-testing. Prior to OGTT, blood pressure and 
a hemocue test (Sweden) to rapidly estimate fasting glucose was per-
formed for exclusion of diabetic participants and for safety reasons. A 
fasting blood sample was collected after 15 min of rest at the − 15 TP. A 
second baseline blood draw was taken 10 min later at the − 5 TP (USA, 
Italy). At TP 0 the glucose tolerance test beverage, containing 75 g 
glucose dissolved in water (USA: Trutol 75 Glucose Tolerance Beverage, 
Thermo Scientific, Middletown VA; Sweden: TopStar75, TopLabs; Italy: 
Bioindustria, L.I.M.) was consumed. Subjects consumed the test 
beverage within 5 min. Subjects were not permitted additional fluid 
consumption during the test. Blood samples were collected 60 min, and 
120 min after consumption of the test glucose beverage. 
2.10.3. Blood collection and analysis 
Blood samples were obtained from an antecubital vein and placed in 
tubes containing a clot activator to obtain serum or sodium/lithium 
heparin to obtain plasma. Serum tubes were held at room temperature 
for at least 15 min and then centrifuged at 4,000×g at 4 ◦C for 15 min 
(3000×g at 4 ◦C for 10 min in Sweden). EDTA-plasma, serum, and 
heparinized-plasma samples were immediately refrigerated/kept on ice, 
processed, and aliquoted into microtubes. Plasma and serum aliquots 
were frozen at – 20 ◦C within 2 h of sample collection, stored at this 
temperature for a maximum of one week, and then stored at − 80 ◦C until 
thawed for analysis. Interim analyses for insulin and glucose were not 
conducted; all samples will be analyzed at the end of the study to 
minimize batch effects. EDTA-plasma samples will be utilized to assess 
insulin and glucose. The center-specific procedures to analyze blood 
samples are described below. 
The Italian center: Serum, heparin, and EDTA-plasma tubes collected 
at fasting and during the MGTT and OGTT testing days were sent to the 
Diabetes Nutrition and Metabolism research laboratories of the Federico 
II University for determination of all relevant cardiometabolic parame-
ters. Glucose was measured by enzymatic colorimetry using an oxidase 
method on an ABX Pentra 400 Autoanalyzer (ABX Diagnostics, Mont-
pellier, France). Insulin was measured by electrochemiluminescence 
immunoassay method by ELISA (DIAsource ImmunoAssays, Nivelles, 
Belgium) on a Triturus Analyzer (Diagnostics Grifols, Barcelona, Spain). 
The Swedish Center: Serum tubes and EDTA-plasma tubes collected 
at fasting and during the MGTT and OGTT testing will be analyzed after 
collection from all participants. Aliquoted plasma and serum samples 
will be analyzed for all relevant cardiometabolic parameters at the 
certified laboratory of the Department of Clinical Chemistry at Uppsala 
University Hospital. HbA1c was analyzed in blood after collection 
(stored at +4 ◦C for maximum of one week) by HPLC method at Klinisk 
Kemi, Laboratoriemedicin, Sahlgrenska Universitetsjukhuset in 
Gothenburg. 
Fig. 2. Meal- and Oral Glucose Tolerance testing day schematic. VAS, visual analog scale.  
Table 1 
Food composition of standardized meal glucose tolerance test meals.  
Low-GI High-GI 
Breakfast Quantity Breakfast Quantity 
Flat bread 75 g Cornflakes 30 g 
Olive Oil, Extra Virgin 10 g Olive Oil, Extra Virgin 18 g 
Eggs, whole, raw 50 g Eggs, whole, raw 50 g 
Ham, dry cured (country 
style) 
38 g Ham, dry cured (country 
style) 
85 g 
Apple, fresh without skin) 150 g Apple, fresh without skin 150 g 
Milk, 1% fat or lowfat, 
lactose free 
244 g Milk, 1% fat or lowfat, 
lactose free 
244 g   
Bread, wholegrain 24 g  
Lunch  Lunch  
Spaghetti noodles, white, 90 g Rice, jasmine 88 g 
Chicken, breast, skinless 58 g Chicken, breast, skinless 70 g 
Tomato sauce, plain, 
regular 
50 g Tomato sauce, plain, 
regular 
50 g 
Olive Oil, Extra Virgin 10 g Olive Oil, Extra Virgin 10 g 
Broccoli, cooked from 
frozen 
90 g Broccoli, cooked from 
frozen 
90 g 
Carrots, cooked from 
frozen 
100 g Carrots, cooked from frozen 100 g 
Apple, fresh, without skin 150 g Apple, fresh, without skin 150 g  
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The United States Center: Serum tubes from the baseline measure-
ment of each MGTT and OGTT testing day were sent to MidAmerica 
Clinical Laboratories (Indianapolis, IN) for determination of fasting 
serum lipid-lipoprotein profile and a complete metabolic panel (fasting 
glucose, GFR, etc.). EDTA-plasma tubes from the baseline measurement 
were sent to MidAmerica Clinical Laboratories (Indianapolis, IN) for 
determination of HbA1c. Glucose was measured by enzymatic colorim-
etry using an oxidase method on a COBAS Integra 400 analyzer (Roche 
Diagnostic Systems, USA, Indianapolis, IN). Insulin was measured by 
electrochemiluminescence immunoassay method on the Elecsys 2010 
analyzer (Roche Diagnotic Systems USA, Indianapolis, IN). 
2.10.4. Anthropometric assessments 
Weight was measured at screening, baseline, and post-testing with 
the participant wearing light clothing and the shoes removed. Body 
weight was measured biweekly in connection with cooking session. BMI 
was calculated as body weight (in kilograms) divided by height (in 
meters) squared. Waist circumference was measured (Gulick II Tape 
Measure, Country Technology Inc., Gays Mills, WI or Seca201 measuring 
tape, Germany) to the nearest 0.5 cm during screening, baseline and 
post-testing at the point of the umbilicus in standing participants with 
arms relaxed along the sides. The participant was asked to take a deep 
breath, and the measurement is performed after the exhalation. Waist 
circumference measurements were performed in duplicate, and then 
averaged. 
The Italian Center: At baseline and after 12-week of intervention 
whole body mass, fat mass, and lean mass were measured using 
Bioelectrical Impedance Analysis (Bodygram, AKERN s.r.l., Italy). The 
measurements were performed according to a standard protocol in the 
morning of the experiment after a 12-h fast, in supine position after 15 
min of rest [39]. Resistance (R) and reactance (X) were measured at the 
flow of a 50-kHz injected mono-frequency current with a coefficient of 
variance <1.5%. 
The Swedish Center: No body composition assessments were 
performed. 
The United States Center: At baseline and post-testing, fasting state 
whole body mass, fat mass, and lean mass were measured using air 
displacement plethysmography (BOD POD, COSMED USA, Concord, CA, 
USA). BOD POD-derived body weights (participants wearing a robe of 
known weight) were obtained at baseline and post-testing. Participants 
were also given a bathroom weight-scale for home use. 
2.10.5. Twenty-four-hour continuous glucose monitoring 
A Medtronic iPro2 Professional CGM device (Northridge, CA, USA) 
was used to obtain 24-h continuous interstitial glucose concentration 
data from study subjects during 6 days (5 days in Italy) of baseline, mid- 
point (USA center only), and post-intervention. The glucose oxidase- 
based sensor was inserted into the abdominal area at least 5 cm away 
from the umbilicus to obtain an interstitial glucose measurement every 
10 s. A recorder stored these data and provided a filtered average of 
these values every 5 min. Self-monitoring glucose readings (finger 
sticks) were performed (Contour®NEXT USB, Ascencia Diabetes Care, 
US) three times per day by subjects to calibrate CGM sensor data. We 
considered 24-h glucose data valid when two or more self-monitoring 
glucose readings were documented [40]. CGM data will be used to 
calculate 24-h interstitial glucose peak, mean, coefficient of variation 
(CV) and total area under the curve (AUC). The group mean and peak 
glucose will be calculated from the individual subjects’ means of 2–4 
days of useable CGM data. Similarly, group CV will be calculated as the 
mean of the ratio of the individual subjects’ standard deviation to mean. 
Additionally, data will be entered into EasyGV platform (University of 
Oxford, Oxford, England) for calculation of glycemic variability and 
mean glucose across each 24-h period. 
2.11. Physical activity assessment 
Participants completed the International Physical Activity Ques-
tionnaire (IPAQ) during baseline weeks, post-intervention, and 3 
months post-intervention. The IPAQ was used to estimate daily ambu-
lation and physical activity and has been shown to have acceptable 
validity and reliability in various nationalities [41]. 
2.12. Sleep quality assessment 
Sleep quality and quantity was evaluated by the Pittsburgh Sleep 
Quality Index (PSQI) [42], the Epworth Sleepiness Scale (ESS) (in USA), 
and by data obtained from a wrist actigraphy monitor (Actiwatch 2, 
Phillips Respironics, Murrysville, PA) in USA and Sweden [43]. The 
PSQI and ESS were administered at baseline, post-testing, and three 
months post-intervention. Actigraphy data were collected for 7 days 
during baseline and post-testing. A sleep log questionnaire to quantify 
sleep and wake times was completed by participants during all 7 days of 
Actiwatch usage (USA). 
Actigraphy data will be processed as previously described by 
O’Connor et al. [44]. Briefly, actigraphy measurements were taken at 
the default 30-s intervals. The actigraphs were scored using the manu-
facturer’s algorithm set at medium sensitivity. Rest intervals can be 
determined in a variety of ways; the most preferable and reliable mea-
surements come from the participant manually pressing the indicator 
button prior to sleeping and immediately upon waking. If there was no 
button press detected, the technician would rely on the recorded sleep 
and wake times provided by the participants. Lastly, if no recorded times 
can be retrieved, the Phillips Actiware (v6.0.7) software default algo-
rithm would estimate sleep and wake times. Time spent in bed, time 
spent sleeping, sleep efficacy (percentage of time spent in bed sleeping), 
onset latency (amount of time to fall asleep once in bed), and total 
number of minutes awake after sleep onset will be assessed and 
reported. 
Subjective data from the PSQI and ESS were used to supplement the 
more objective actigraphy data. With regard to the PSQI, a higher global 
sleep score (0–21 arbitrary units [AU]) indicates poorer sleep; a global 
sleep score ≥ 5 AU is classified as “poor sleep” [42,44]. With regard to 
the ESS, a higher ESS score (0–24 AU) indicates greater daytime sleep-
iness; a score > 10 AU indicates excessive daytime sleepiness [45]. The 
ESS and PSQI are found to be weakly (but significantly) associated with 
each other, and are posited to evaluate different aspects of sleep [46]. 
2.13. Subjective health and well-being assessment 
The Medical Outcomes Study 36-item short-form questionnaire (SF- 
36v2), administered at baseline, post-testing, and at the 3 month follow- 
up, was used to measure perceived physical and emotional well-being 
[47,48]. Raw SF-36v2 questionnaire data will be entered into Optum 
ProCoRE (Optum Inc., Eden Prairie, MN) for algorithmic transformation 
into domains of perceived health and wellness including: physical 
functioning, role limitations due to physical health, bodily pain, general 
health, vitality, social functioning, role limitations due to emotional 
health, and mental health. Scores are presented on a 0–100 scale, with 
higher scores indicative of greater perceived health and wellness. 
2.14. Fecal microbiota 
Spot fecal samples were collected at baseline and post-testing for all 
participants. The samples were collected in specific devices (Easy-
Sampler CollectionKit, GP Medical Devices ApS, Denmark) and were 
placed in the freezer right after collection and brought to the clinic 
frozen. Microbial DNA from fecal samples will be extracted for analysis 
of the gut microbiota by deep 16S rRNA sequencing using Illumina 
MiSeq [49]. The Bristol stool scale was used to assess defecation habits 
and bowel function during the stool collection day [50]. Additionally, 
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participants specified recent usage of antibiotics on the day of the fecal 
sample collection. The composition of the gut microbiota will be 
analyzed to provide possible mechanistic explanations underlying dif-
ferential responses of participants (identifying 
responders/non-responders) on higher-versus lower- GI dietary in-
terventions and effects on gut microbiota composition caused by the 
interventions. 
2.15. Metabolomics assessment 
Plasma samples collected at baseline and post-testing will be 
analyzed for untargeted metabolomics at the Swedish center. Untar-
geted metabolomics will be performed using 0.2 mL heparin-plasma 
from samples taken at TP-15, +120, 240, and 480 min from test meals 
on MGTT test days. Plasma samples will be processed and analyzed in 
four different modes (reverse phase/HILIC chromatography in positive/ 
negative ionization, respectively) on a LC-QTOF-MS instrument ac-
cording to an established protocol [51]. This will ensure the most 
comprehensive collection of metabolite features. Data will be 
pre-processed and analyzed according to a recently developed 
data-treatment pipeline developed by the Swedish group [52,53]. 
2.16. Study outcomes 
The primary outcome of the MEDGI-Carb trial were changes in 
postprandial insulin concentrations during the 8-h MGTT. Postprandial 
insulin, of which power calculations were based on, was chosen as the 
primary endpoint because, in the presence of a well-functioning beta 
cell, any improvement in plasma glucose concentrations due to a dietary 
intervention would slowly be compensated by variation in insulin 
secretion triggered by glucose values. We prioritized assessments of 
insulin over C-peptide because C-peptide is not extracted by the liver 
[54], and therefore is not a good marker of derangements in post-
prandial insulin sensitivity. Assessment of postprandial insulin was 
complemented by the principle secondary outcome – postprandial 
glucose, of which power calculations indicated a similar number of 
participants to be recruited. Secondary outcomes of relevant parameters 
of blood glucose metabolism were operationalized as fasting glucose, 
fasting insulin, HbA1c, and 24-h CGM responses, collected at baseline, 
mid-testing (USA-only), and post-testing. Fasting plasma glucose, 
HbA1c, 2-h OGTT plasma glucose, homeostatic model assessment of in-
sulin resistance (HOMA-IR) [55], postprandial blood glucose and insulin 
responses and CGM all measure different aspects of glucose metabolism 
[56]. We consider this to be a strength of the current research. While 
these measures are strongly correlated [57], inclusion of multiple 
measures of glucose control add additional context. For example, HbA1c 
not only accurately predicts CGM-derived glucose values, but also adds 
additional information to the model for more accurate prediction of 
average glucose [58]. Conversely, it may not be sufficient to evaluate 
changes in postprandial glucose and insulin metabolism in non-diabetic 
people [59]. 
There are strengths and limitations to each of these measurements in 
isolation. Long considered a “gold-standard” for diagnosis of glucose 
intolerance and diabetes, the OGTT is the most sensitive measure of 
impaired glucose homeostasis, as increases in postprandial glucose re-
sponses precede increases in fasting glucose [60]. However, the OGTT 
suffers from a well-documented high degree of intra-individual vari-
ability (CV = 16.7%) [61]. Fasting plasma glucose has considerably less 
variability than 2-h OGTT glucose values and is considered the preferred 
diagnostic test by the American Diabetes Association [62]. However, 
there is still large biological variability in fasting plasma glucose relative 
to HbA1c [61]. While HbA1c measurements may present with the 
greatest reliability (CV < 1%) [63], there are notable discrepancies in 
readings according to iron status [64] and race/ethnicity [65], inde-
pendent of glucose concentrations. Further, HbA1c would not be ex-
pected to respond completely to our dietary-intervention of a length 
(~84 days) less than the average lifespan of hemoglobin (~120 days). 
Moreover, it is not sufficiently sensitive to appreciate small changes in 
glucose metabolism in non-diabetic individuals. With respect to CGM, 
glucose data derived from CGM may be less accurate than venous 
plasma glucose on a point-by-point basis [66], but it provides valuable 
information on glucose excursions and overall variability, which may 
contribute more to cardiometabolic disease risk than chronically 
elevated glucose [67]. 
We recognize the importance of study measurements translating to 
situations individuals find themselves in the real world. Therefore, the 
MGTT provides additional context and serves as an important practical 
translation of this work by documenting the glycemic and insulinemic 
responses to complete mixed meals. The MGTT serves as a ‘nested acute 
study’ within the overall trial, whereby the absolute difference in gly-
cemic responses to high- and low-GI meals at any individual timepoint is 
not of particular importance, but the changes in the relative glycemic 
response over the course of the intervention can elucidate the impor-
tance of the background diet in modulating the glycemic response to 
acute feeding. 
Effects of the high vs low GI MED-style HEP on the plasma metab-
olome and gut microbiota will be analyzed as exploratory analyses. 
Moreover, we also plan to address the role of gut microbiota composi-
tion and plasma metabolome at baseline as determinants of the 
response/non-response to intervention with regards to acute glycemic 
and long-term cardiometabolic risk factors. Molecular effects of the MED 
diet on cardiometabolic risk factors in these aspects has recently been 
reviewed by Tuttolomondo et al. [68]. 
2.17. Data analysis and sample size estimates 
Both “intention-to-treat” and “per-protocol” data analyses will be 
performed. The primary analyses will follow the intention-to-treat plan, 
where participants will be analyzed regardless of compliance or 
completion of study procedures. A priori sensitivity analyses using a ‘per 
protocol’ plan will be conducted, where noncompliant participants will 
be excluded. A repeated measures, two-way ANCOVA will be used to 
assess main effects of diet, time, and diet by time interactions plus 
center. Potential covariates used in models include age, sex, height, 
weight, BMI, baseline dependent variables, medication usage, and 
smoking status. All completers (goal of 60 subjects per group, 180 
subjects total) will be tested — providing greater than 80% power to 
detect a 30% differential response between the dietary interventions for 
the primary endpoint (postprandial insulin) with similar variation re-
ported in the study by Giacco et al. [69]. An equal number of study 
participants are anticipated to be recruited in each of the three centers. 
Further analyses will be performed after identification of appropriate 
subgroups taking into consideration several parameters, i.e. sex, severity 
of metabolic derangements, degree of overweight, relevant features of 
the baseline diet, and operating center. All statistical analyses will be 
done with consultation from the NIH Indiana Clinical and Translational 
Biostatistics Core services staff (www.indianactsi.org). All statistical 
analyses will be performed with SAS statistical software version 9.4 (SAS 
Institute, Cary, NC). 
3. Discussion 
The MEDGI-Carb trial aimed to evaluate the relevance of the GI in 
the context of a MED-style HEP. The clinical utility of the GI is still under 
debate, despite decades of research and a plethora of trials [12–14]. 
Conversely, there is relatively less evidence — particularly experimental 
evidence — on the health-promoting effects of a MED-style HEP [70]. 
The results of the MEDGI-Carb trial have the potential to answer 
important questions pertaining to both Mediterranean-style eating pat-
terns and the relevancy of the long-term effects of GI in a non-diabetic 
population. The results of the MEDGI-Carb trial have the potential to 
inform health care providers and the public regarding the importance of 
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consuming low GI carbohydrate foods as part of a Mediterranean-style 
eating pattern. 
The MEDGI-Carb trial utilized several strategies to successfully 
implement dietary control, including dietary counseling, provision of 
specific study foods to participants during the intervention, frequent 
checks and documentation of food intake (Sweden, Italy) or completion 
of itemized menu checklists (Sweden, USA), and offering cooking classes 
to enhance participant self-efficacy. Further, the robustness of the pri-
mary manipulated variable (GI of the carbohydrate foods) was ensured 
through independent analyses to ensure that the GI of the carbohydrate 
foods were sufficiently different between the low- and high-GI groups. 
Additional strengths of the MEDGI-Carb study include strong clinical 
design features such as randomization, blinding, provision of tools to 
participants to enhance compliance to study protocols (weight scales, 
measuring tools, etc. In US), and an appropriate sample size with respect 
to effect size and power based on previous research. These features place 
the current research in a strong position to investigate GI and dietary 
patterning in a meaningful way. 
In addition to the numerous avenues we have taken in assessing 
glucose homeostasis, we are positioned to answer other emerging 
questions in nutrition science such as, 1) to what extent the gut micro-
biome and specific metabolic profiles may moderate or indicate dietary 
intervention-induced changes in cardiometabolic health via collection 
of blood and stool samples, 2) the impact of dietary interventions on 
indices of sleep quality via objective (Actiwatch) and subjective (PSQI, 
ESS) measures, and 3) ratings of subjective health and well-being via 
collection of self-rated health assessments (SF-36v2). Collectively, the 
current research has the potential to provide a wealth of knowledge 
which can address outstanding questions in regard to GI and 
Mediterranean-style eating patterns, as well as generate promising new 
leads and hypotheses. 
There may be important implications from this research regardless of 
whether the results support or refute our hypothesis. If our hypothesis is 
supported and there are greater improvements in indices of glucose 
control in the low-GI group relative to the high-GI group, then these 
novel findings would provide additional support for the potential rele-
vancy of the GI in a complete mixed diet among non-diabetic pop-
ulations. Low GI and low glycemic load are inherent elements of a 
traditional Mediterranean diet [71]. If the more traditional low-GI 
version of the Med HEP in this study is more effective than the 
high-GI version, this would support the inclusion of low-GI foods as part 
of a Med HEP. Conversely, if the results are inconsistent with our hy-
pothesis, this may suggest that differences in GI are not robust or masked 
in the context of an overall healthy eating pattern. Therefore, the study 
design and hypotheses put forth are unconditionally robust, as results 
supportive or unsupportive of the hypothesis provide new directions for 
future research and recommendations. 
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